ALK and non-small cell lung carcinoma: Therefore, we conducted a comprehensive network meta-analysis (NMA) using additional data and methodological approaches to compare the safety and efficacy of current therapies in first- or second-line treatment of ALK-positive NSCLC patients across various subgroups, and to evaluate the impacts of these therapies on patients’ quality of life (QoL).